Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials
From MaRDI portal
Publication:1658329
DOI10.1016/J.CSDA.2011.03.014zbMath1464.62160OpenAlexW2043530289WikidataQ59901553 ScholiaQ59901553MaRDI QIDQ1658329
Brian M. Bot, Tomasz Burzykowski, Lindsay A. Renfro, Marc Buyse, Daniel J. Sargent, Qian Shi
Publication date: 14 August 2018
Published in: Computational Statistics and Data Analysis (Search for Journal in Brave)
Full work available at URL: http://hdl.handle.net/1942/12137
Computational methods for problems pertaining to statistics (62-08) Applications of statistics to biology and medical sciences; meta analysis (62P10)
Related Items (3)
Center-within-trial versus trial-level evaluation of surrogate endpoints ⋮ A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials ⋮ Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
Cites Work
- Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
- The evaluation of surrogate endpoints.
- A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence
- Numerical Optimization
- The validation of surrogate endpoints in meta-analyses of randomized experiments
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
This page was built for publication: Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials